European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
Zawartość zarchiwizowana w dniu 2024-05-24

Quality of life following adherence therapy for people disabled by schizophrenia and their carers (QUATRO)

Cel

Ant psychotic medication has well-established effectiveness in the treatment of people with schizophrenia. However, adherence to medication is a very common problem, and non-adherence increases the risk of relapse disability, and poor quality of life. The "Quality of Life following Adherence Therapy for People Disabled by Schizophrenia and their Carers" study is a randomised controlled trial and will investigate the effectiveness and cost effectiveness of adherence therapy designed to improve quality of life among schizophrenic patients and their carers. The study is expected to contribute to evidence-based practice in the care for people who suffer from schizophrenia, and their carers, across Europe.

Zaproszenie do składania wniosków

Data not available

System finansowania

CSC - Cost-sharing contracts

Koordynator

KING'S COLLEGE LONDON
Wkład UE
Brak danych
Adres
De Crespigny Park, Denmark Hill
SE5 8AF LONDON
Zjednoczone Królestwo

Zobacz na mapie

Koszt całkowity
Brak danych

Uczestnicy (3)